A Randomized Double-Blind Study on Acupuncture Point Regulatory-Control Combined with Clomipramine for Obsessive-Compulsive Disorders

FENG Bin1; ZHU Ruiming2; XU Fangzhong1; LIU Lanying1; CHEN Jiong1; LV Yangyang3; WANG Peirong1

doi:10.13288/j.11-2166/r.2013.09.028

您当前的位置：

首页 >

文章列表页 >

A Randomized Double-Blind Study on Acupuncture Point Regulatory-Control Combined with Clomipramine for Obsessive-Compulsive Disorders

更新时间：2021-11-17

- A Randomized Double-Blind Study on Acupuncture Point Regulatory-Control Combined with Clomipramine for Obsessive-Compulsive Disorders
- Journal of Traditional Chinese Medicine Vol. 54, Issue 9, Pages: 762-765(2013)
- 作者机构：
  
  1. 浙江省立同德医院
  2. 浙江省义乌市中医医院
  3. 浙江中医药大学
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2013.09.028
  CLC： R749.7
- Published：2013
- 稿件说明：
移动端阅览
[1]冯斌,朱锐明,徐方忠,刘兰英,陈炯,吕洋洋,王佩蓉.穴位刺激调控法联合小剂量氯米帕明片治疗强迫症81例随机双盲临床研究[J].中医杂志,2013,54(09):762-765.

FENG Bin1, ZHU Ruiming2, XU Fangzhong1, et al. A Randomized Double-Blind Study on Acupuncture Point Regulatory-Control Combined with Clomipramine for Obsessive-Compulsive Disorders[J]. Journal of Traditional Chinese Medicine2013, 54(9): 762-765.
[1]冯斌,朱锐明,徐方忠,刘兰英,陈炯,吕洋洋,王佩蓉.穴位刺激调控法联合小剂量氯米帕明片治疗强迫症81例随机双盲临床研究[J].中医杂志,2013,54(09):762-765. DOI： 10.13288/j.11-2166/r.2013.09.028.

FENG Bin1, ZHU Ruiming2, XU Fangzhong1, et al. A Randomized Double-Blind Study on Acupuncture Point Regulatory-Control Combined with Clomipramine for Obsessive-Compulsive Disorders[J]. Journal of Traditional Chinese Medicine2013, 54(9): 762-765. DOI： 10.13288/j.11-2166/r.2013.09.028.

摘要

目的观察穴位刺激调控法合并小剂量氯米帕明片治疗强迫症的临床疗效。方法将160例强迫症患者随机分为研究组81例和对照组79例

两组均先经过药物清洗期2周后开始双盲治疗。研究组给予穴位刺激加行为疗法治疗

每日1次

每次30min

每周5次

并服用每片12.5mg剂型的氯米帕明片;对照组服用每片25mg剂型的氯米帕明片并接受模拟穴位刺激调控法治疗。两组服药方法均为第1天1片

以后每隔1天增加1片

第11天增加至6片

两组均治疗12周。治疗前后采用Y-Brown强迫症量表（Y-BOCS）、汉密尔顿抑郁量表（HAMD）、简明精神病量表（BPRS）、副反应量表（TESS）评定临床疗效和不良反应。结果研究组痊愈率为48.15%

对照组为30.38%;研究组总有效率为95.10%

对照组为87.30%

两组比较差异均有统计学意义（P<0.05）。两组患者治疗后第2、4、6、8、12周Y-BOCS评分总分与治疗前比较差异均有统计学意义（P<0.05或P<0.01）;治疗后第4、6、8、12周Y-BOCS评分总分与对照组比较差异均有统计学意义（P<0.05或P<0.01）。两组治疗12周后Y-BOCS强迫思维和强迫行为评分、HAMD、BPRS量表评分与治疗前比较差异均有统计学意义（P<0.01）;两组治疗后Y-BOCS强迫思维和强迫行为、HAMD评分差异均有统计学意义（P<0.05）

而BPRS评分差异无统计学意义（P>0.05）。结论穴位刺激调控法合并小剂量氯米帕明片治疗强迫症临床疗效肯定

且不良反应少。

Abstract

Objective To observe the therapeutic effect of acupuncture point regulatory-control（APRC）combined with lowdose clomipramine for obsessive-compulsive disorders（OCD）.Methods Totally 160OCD patients were randomized into the study group and control group

with 81and 79in each.Both groups were given the double-blind treatment after 2-week washout period.The study group was given 30min APRC and behavioral therapy once daily

5times weekly and given clomipramine（12.5mg/tablet）orally.The control group was given clomipramine（25mg/tablet）orally and analog APRC.The medication method in both groups was:1tablet daily since the 1st day

then 1tablet added every other day and increased to 6tablets on the 11th day.Finally

the dose of clomipramine was 75mg/d in the study group and 150mg/d in the control group.Both groups were treated for 12weeks.The therapeutic effect and adverse reactions were evaluated with Yale-Brown ObsessiveCompulsive Scale（Y-BOCS）

Hamilton Depression Scale（HAMD）

Brief Psychiatric Rating Scale（BPRS）and Treatment Emergent Symptom Scale（TESS）.Results The cure rate in the study group and control group was 48.15% and 30.38% respectively

with a significant difference between groups（P<0.05）.The total effective rate of the study group and the control group was 95.10% and 87.30% respectively

with significant difference between groups（P<0.05）.There were significant differences in the Y-BOCS scores between before and after treatment in both groups in the 2nd

4th

6th

8th and 12th week of treatment（P<0.05or P<0.01）

especially in the study group in the 4th

6th

8th and 12th week of treatment（P<0.05or P<0.01）.There were significant differences in the obsessions score and compulsions score of Y-BOCS

HAMD scores and BPRS scores between before and after treatment in both groups after 12weeks of treatment（P<0.01）

especially in the obsessions score and compulsions score of Y-BOCS and HAMD scores in the study group（P<0.05）.Conclusion Comparing with clomipramine used singly

the combo therapy of APRC and low-dose clomipramine is more effective for OCD with fewer adverse reactions and good safety.

关键词

Keywords

references

查看原文

Views

173

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Comparative Analysis of Clinical Efficacy of Electro-acupuncture and Simple Acupuncture in the Treatment of First-Episode Mild-to-Moderate Depression

Clinical Observation on 35 Cases of Chronic Hepatitis B Complicated with Depression Treated with Changyu Xiaoyao Fang（菖郁逍遥方） Combined with Entecavir Dispersible Tablets

Clinical Observation on Jieyu Jiaonang（解郁胶囊） Combined with Paroxetine Treating 50 Depression Cases

Hongjingtian [Rhodiola]Capsule in Treating 147 Patients with Mild or Moderate Major Depressive Disorder Deficiency Syndrome of both Heart and Spleen: A Randomize-Controlled,Double-Blind,Placebo Clinical Trial

Clinical Observation on Xiegan Anshen Formula for 100 Cases of Generalized Anxiety Disorder

Related Author

SUN Haishu

WANG Xiaoling

ZHANG Honglin

HAN Duan

LIANG Huiqing

WU Chuncheng

TANG Jinmo

YANG Jia’en

Related Institution

School of Acupuncture, Moxibustion and Tuina, Beijing University of Chinese Medicine

Guang’ anmen Hospital,China Academy of Chinese Medical Sciences

Institute of Information on Traditional Chinese Medicine,China Academy of Chinese Medical Sciences

北京中医药大学针灸推拿学院中国中医科学院广安门医院中国中医科学院中医药信息研究所

Medical College,Xiamen University

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰